Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-5670d vs Comirnaty in Children 5–11 Years (Omicron XBB.1.5)
jRCT2031230423Phase 3Suspended
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of duvofameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: GMT of neutralising antibodies against SARS-CoV-2 Omicron XBB.1.5 at 4 weeks (prior infection or vaccination subset) and Seroresponse rate of neutralising antibodies against SARS-CoV-2 Omicron XBB.1.5 at 4 weeks (prior infection or vaccination subset). Started Jan 2024; status: suspended.
02
Drugs
duvofameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031230423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230423.